Becton, Dickinson and Company (BD) Expands U.S. Manufacturing to Strengthen Medical Device Supply Chain

On January 15, 2025, BD (Becton, Dickinson and Company) Announced additional investments to expand its U.S. manufacturing network, thereby improving the production of critical medical devices such as IV catheters, needles, and syringes. The objective of these endeavors is to fortify the resilience of the supply chain and address the persistent requirements of the U.S. healthcare system.

In 2024, BD allocated more than USD 10 million to the installation of new hypodermic and needle production lines at its Connecticut and Nebraska facilities. One line is currently operational, and additional lines are scheduled to be introduced in the near future.

This expansion will result in an annual increase of hundreds of millions of units in the production capacity of the United States for safety-engineered injection devices and conventional syringes, which will increase by over 40% and more than 50%, respectively. The two facilities have also hired over 215 employees as a result of the expansion.

Looking ahead, BD intends to allocate more than USD 30 million in 2025 to the expansion of IV catheter production at its Utah facility. This is the result of a USD 2 million investment in 2024, which resulted in a 40 million units annual increase in IV catheter output.

BD’s dedication to providing the U.S. healthcare system with innovative, high-quality medical devices is emphasized by this investment.

Official Statement: Click here